Efficacy and safety of Y90 radioembolization combined with targeted therapy and immunotherapy in patients with unresectable hepatocellular carcinoma: a dual-center, retrospective study.

BMC Cancer · 2026 · PMC13169584 · PMID 41923204

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

did not reach statistical significancep = 0.087so close (0.05 < p ≤ 0.1)

10.0 months; HR 0.66, p = 0.0002), while overall survival did not reach statistical significance (HR 0.80, p = 0.087) [ 17 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.